SCAdult & adolescent ≥13 yr 0.5 mL dose at elected date & 2nd 0.5 mL dose 4-8 wk later. Childn 12 mth-12 yr 0.5 mL dose. 2nd 0.5 mL dose should be given a min of 3 mth later.
Hypersensitivity. History of anaphylactoid reaction to neomycin. Individuals w/ blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the bone marrow or lymphatic systems. Individuals receiving immunosuppressive therapy or on immunosuppressants. Individuals w/ primary & acquired immunodeficiency states including those who are immunosuppressed in association w/ AIDS or other clinical manifestations of infection w/ HIV, cellular immune deficiencies & hypogammaglobulinemic & dysgammaglobulinemic states. Family history of congenital or hereditary immunodeficiency. Active untreated TB. Any febrile resp illness or other active febrile infection. Pregnancy.
Adequate treatment provisions including epinephrine inj should be readily available for immediate use if an anaphylactoid reaction occur. Do not inj intravascularly. Defer vaccination for at least 5 mth following blood/plasma transfusions or administration of immune globulin/varicella zoster immune globulin (VZIG). Do not give any immune globulin including VZIG for 2 mth thereafter following administration unless its use outweighs the benefits. Avoid salicylates for 6 wk after vaccination. Obtain previous immunization history of vaccinee. Defer vaccination in patients w/ family history of congenital or hereditary immunodeficiency until patient's own immune system has been evaluated. Avoid close association w/ susceptible high-risk individuals for up to 6 wk. Avoid pregnancy for 3 mth following vaccination. Lactation. Childn & young adults who are known to be infected w/ HIV w/ & w/o immunosuppression evidence. Childn <1 yr; not recommended in infant <12 mth.
Sign Out
53806049-81a2-49c4-a91f-aec500953497.GIF)
